Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
复制标题
DOI：
10.1159/000157075
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
J. Mier;F. Aronson;R. Numerof;G. Vachino;M. Atkins
中科院分区：
文献类型：
--
作者：
J. Mier;F. Aronson;R. Numerof;G. Vachino;M. Atkins
IL-2免疫治疗是肾细胞癌和恶性黑色素瘤治疗的重大突破。目前，大多数IL-2方案的毒性是严重的，并且对于不熟悉与其使用相关的无数副作用的临床医生来说是禁止的。阐明淋巴因子诱导肿瘤消退、血管渗漏综合征和其他副作用的机制将使IL-2更安全有效地使用。
Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.